A. Dual antiplatelet therapy (DAPT) B. Beta-blocker C. Lipid lowering therapy D. Warfarin

A. Less than 130 mg/dL B. Less than 100 mg/dL C. Less than 70 mg/dL D. Less than 40 mg/dL

A. Mr. RS should begin an angiotensin-converting enzyme inhibitor (ACE-I) B. Mr. RS should not begin RAAS inhibitor therapy due to an absence of heart failure C. It would be reasonable to start Mr. RS on an angiotensin II receptor blocker (ARB) D. Mr. RS should begin an aldosterone blocker but not an ACE-I or ARB

A. Clopidogrel B. Aspirin C. Prasugrel D. Ticagrelor

A. Mr. RS should reduce his aspirin dose to 81 mg oral daily if starting ticagrelor B. Mr. RS should discontinue aspirin six months after a bare metal stent C. Mr. RS should discontinue aspirin when starting a P2Y12 inhibitor D. 325 mg of aspirin daily is more effective than 81 mg of aspirin daily

A. One month B. Three months C. Six months D. 12 months

A. 10% B. 20% C. 30% D. 40% E. 50%

A. Single marital status B. Depression C. CABG surgery D. Older age

A. One month after discharge B. Three months after discharge C. Six months after discharge D. One year after discharge

A. Patient-reported adherence was better in the intervention group B. A higher rate of 75% or greater Proportion of Days Covered (PDC) for beta-blocker therapy in the intervention group C. Medication Therapy Management (MTM) resulted in better lipid profiles for patients in the intervention group D. Medication Therapy Management (MTM) resulted in better blood pressure control in the intervention group